Drug Profile

PRS 400

Alternative Names: PRS-400

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pieris Pharmaceuticals
Developer Palvella Therapeutics
Class Lipocalins
Mechanism of Action Jagged-1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Lung disorders

Most Recent Events

13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
18 Jul 2023 PRS 400 is available for licensing as of 18 Jul 2023. https://www.pieris.com/
23 Nov 2022 Preclinical trials in Lung disorders in USA (Inhalation) (Pieris Pharmaceuticals pipeline, November 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com